drugset / Trial / NCT00607308
A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to examine the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single dose of PF-04360365 in Japanese subjects with mild to moderate Alzheimer's Disease.
Timeline
- Start
- 2008-02
- Primary completion
- 2010-10
- Completion
- 2010-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ponezumab | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Subject | Ponezumab | Monoclonal antibody | 0.5 mg/kg | Intravenous |
| Subject | Ponezumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Ponezumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Ponezumab | Monoclonal antibody | 10 mg/kg | Intravenous |